Literature DB >> 2838984

Live viral vaccines for respiratory and enteric tract diseases.

R M Chanock1, B R Murphy, P L Collins, K V Coelingh, R A Olmsted, M H Snyder, M K Spriggs, G A Prince, B Moss, J Flores.   

Abstract

In its programme for accelerated development of vaccines for viral respiratory and enteric tract diseases the WHO has assigned a very high priority to respiratory syncytial virus (RSV), parainfluenza viruses and rotaviruses. There is also some interest in alternative approaches to immunization against influenza viruses because of the failure of inactivated vaccines to provide complete and reasonably durable immunity. Current attempts to develop satisfactorily attenuated viruses for use in prevention of disease caused by the above viral pathogens are described.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838984     DOI: 10.1016/s0264-410x(88)80014-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Nebulized live-attenuated influenza vaccine provides protection in ferrets at a reduced dose.

Authors:  Jennifer Humberd Smith; Mark Papania; Darin Knaus; Paula Brooks; Debra L Haas; Raydel Mair; James Barry; S Mark Tompkins; Ralph A Tripp
Journal:  Vaccine       Date:  2011-11-07       Impact factor: 3.641

Review 2.  Rotavirus gene structure and function.

Authors:  M K Estes; J Cohen
Journal:  Microbiol Rev       Date:  1989-12

3.  Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice.

Authors:  Jennifer Humberd Smith; Paula Brooks; Scott Johnson; S Mark Tompkins; Koren M Custer; Debra L Haas; Raydel Mair; Mark Papania; Ralph A Tripp
Journal:  Vaccine       Date:  2011-02-05       Impact factor: 3.641

4.  Influenza hemagglutinin (HA) stem region mutations that stabilize or destabilize the structure of multiple HA subtypes.

Authors:  Lauren Byrd-Leotis; Summer E Galloway; Evangeline Agbogu; David A Steinhauer
Journal:  J Virol       Date:  2015-02-04       Impact factor: 5.103

Review 5.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

6.  Coronavirus infection in the laboratory rat: immunization trials using attenuated virus replicated in L-2 cells.

Authors:  D H Percy; R A Scott
Journal:  Can J Vet Res       Date:  1991-01       Impact factor: 1.310

7.  Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.

Authors:  F M Piazza; S A Johnson; M E Darnell; D D Porter; V G Hemming; G A Prince
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine.

Authors:  Rachel Groppo; Joshua DiNapoli; Kwang Il Jeong; Michael Kishko; Nicholas Jackson; Harold Kleanthous; Simon Delagrave; Linong Zhang; Mark Parrington
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

9.  Host defense mechanism-based rational design of live vaccine.

Authors:  Yo Han Jang; Young Ho Byun; Kwang-Hee Lee; Eun-Sook Park; Yun Ha Lee; Yoon-Jae Lee; Jinhee Lee; Kyun-Hwan Kim; Baik Lin Seong
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

10.  Coronavirus immunogens.

Authors:  L J Saif
Journal:  Vet Microbiol       Date:  1993-11       Impact factor: 3.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.